Hematology

Latest News

While both are anti-CD20 antibodies, obinutuzumab is a glycoengineered type II CD20 antibody, and rituximab is a type I CD20 antibody, meaning a different mode of binding to CD20 antigen. | Image credit: Eleni - stock.adobe.com
Long-Term Data Show Favorable Survival Outcomes With G-Clb in Treatment-Naive CLL

May 1st 2025

Participants in the CLL11 trial and a smaller group of patients followed after study completion showed improved overall survival with obinutuzumab and chlorambucil (G-Clb) compared with chemotherapy plus rituximab or chemotherapy alone for chronic lymphocytic leukemia (CLL).

Researchers analyzed matched cohorts of patients who received either decitabine-cedazuridine with venetoclax or decitabine-cedazuridine alone to determine how the addition of venetoclax impacts outcomes in higher-risk MDS and CMML. |Image credit: syahrir - stock.adobe.com
Adding Venetoclax to Decitabine-Cedazuridine Improves Response in MDS Subgroups

April 25th 2025

Tailored approaches help patients with MM find the regimen that works best for them, which improves quality of life and outcomes | image credit: Dzmitry - stock.adobe.com
Tailored Dosing for MM Matters More Than Drug Count: Ajai Chari, MD

April 25th 2025

The investigators found that people with MPNs and at least one CVRF had an increased risk of both death and arterial or venous thrombosis. | Image credit: Dr_Microbe - stock.adobe.com
Cardiovascular Risk Factors Impact Outcomes in MPNs

April 21st 2025

While pausing therapy did not affect response to vaccination, the investigators noted that participants who paused therapy did have higher rates of self-reported lymphadenopathy. | Image credit: Konstantin Yuganov - stock.adobe.com
Pausing BTK Inhibitors Does Not Strengthen COVID Vaccination in CLL

April 18th 2025

Expanding Horizons: The Present and Future of Bispecific Antibodies Across Oncology

Experts explore the latest bispecific antibody approvals and clinical applications, discuss barriers in community oncology, address management of cytokine release syndrome, and consider how these therapies can expand patient access to care.

AJMC Peer Exchange logo

More News

Patients With Low-Risk Multiple Myeloma Precursor Can Progress to the Disease in Just 5 Years
August 10th 2019

Patients With Low-Risk Multiple Myeloma Precursor Can Progress to the Disease in Just 5 Years

Laura Joszt, MA
Patients with monoclonal gammopathy of undetermined significance (MGUS), a precursor to multiple myeloma (MM), can progress from low- or intermediate-risk to MM in just 5 years, according to researchers who are now recommending all patients with MGUS undergo blood testing and risk assessment.
Having a Close Relative With Blood Cancer Boosts One's Own Risk
August 8th 2019

Having a Close Relative With Blood Cancer Boosts One's Own Risk

Mary Caffrey
The study's lead author said more work is needed to develop screening protocols for people who may face familial risk of a blood cancer.
Dr Catherine Diefenbach Discusses Reducing Toxicity When Treating Lymphoma
August 2nd 2019

Dr Catherine Diefenbach Discusses Reducing Toxicity When Treating Lymphoma

Pairing low doses of chemotherapy with newer, targeted drugs can help prevent high toxicity, said Catherine Diefenbach, MD, director of clinical lymphoma at the NYU Langone Perlmutter Cancer Center.
Ibrutinib–Rituximab Improves Survival Compared With Current Treatment for Chronic Lymphocytic Leukemia
August 1st 2019

Ibrutinib–Rituximab Improves Survival Compared With Current Treatment for Chronic Lymphocytic Leukemia

Mary Caffrey
Patients with chronic lymphocytic leukemia (CLL) will likely see a new standard of care based on outcomes in a phase 3 trial for patients treated with a combination of ibrutinib and rituximab.
Mustang Bio Receives Orphan Drug Designation for Investigational CAR T-Cell Therapy for AML
July 27th 2019

Mustang Bio Receives Orphan Drug Designation for Investigational CAR T-Cell Therapy for AML

AJMC Staff
Orphan drug status applies to therapies that will treat fewer than 200,000 patients in the United States.
Study Finds Common, Lethal Cancers Need More Funding
July 26th 2019

Study Finds Common, Lethal Cancers Need More Funding

Laura Joszt, MA
Some cancers, such as breast cancer and leukemia, were well-funded compared with their incidence, mortality, and person-years of life lost, while others, such as gastrointestinal and brain cancers, were all poorly funded.
Researchers Identify 5 Risk Factors for Blood Clots in Patients With MM Treated With IMiDs
July 19th 2019

Researchers Identify 5 Risk Factors for Blood Clots in Patients With MM Treated With IMiDs

Laura Joszt, MA
Venous thromboembolism (VTE) is a significant complication for patients with multiple myeloma (MM) who are being treated with immunomodulatory drugs (IMiDs), and a new assessment model may help to predict VTE in this population.
VA Study: Black Patients With MM See Better Survival Than White Patients With Equal Access to Therapy
July 17th 2019

VA Study: Black Patients With MM See Better Survival Than White Patients With Equal Access to Therapy

Mary Caffrey
African Americans are twice as likely to get multiple myeloma (MM) as whites, but they get the disease at younger ages.
Dova Pharmaceuticals Launching Avatrombopag for Chronic Immune Thrombocytopenia
July 13th 2019

Dova Pharmaceuticals Launching Avatrombopag for Chronic Immune Thrombocytopenia

Alison Rodriguez
With the FDA approval of a supplemental New Drug Application (sNDA) expanding the use of avatrombopag (Doptelet) for patients with chronic immune thrombocytopenia (ITP), Dova Pharmaceuticals said recently it will begin marketing the drug for the new indication in the middle of July.
Identifying Multiple Myeloma Treatment Patterns by Age and Region
July 12th 2019

Identifying Multiple Myeloma Treatment Patterns by Age and Region

Laura Joszt, MA
A poster abstract evaluated real-world treatment patterns by region and age to better understand these issues in order to address them.
Lenalidomide Proves Effective in Treating Smoldering Multiple Myeloma
July 6th 2019

Lenalidomide Proves Effective in Treating Smoldering Multiple Myeloma

Sara Karlovitch
A new study by Mayo Clinic Researchers calls into question the current standard of care for treating smoldering multiple myeloma.
SIRT1 Plays Key Role in Preventing Leukemia Stem Cell Elimination
July 4th 2019

SIRT1 Plays Key Role in Preventing Leukemia Stem Cell Elimination

Sara Karlovitch
Researchers from the the University of Alabama finds the SIRT1 protein plays a key role in preventing chronic myeloid leukemia stem cell elimination.
Final Thoughts on Approach to Multiple Myeloma Treatment
June 28th 2019

Final Thoughts on Approach to Multiple Myeloma Treatment

Biochemical Versus Symptomatic Relapse Treatment Choices in MM
June 28th 2019

Biochemical Versus Symptomatic Relapse Treatment Choices in MM

Managing Discrepancies in NCCN and Payer Guidelines in Multiple Myeloma
June 28th 2019

Managing Discrepancies in NCCN and Payer Guidelines in Multiple Myeloma

Patient Cost Implications in Multiple Myeloma Treatment
June 28th 2019

Patient Cost Implications in Multiple Myeloma Treatment

Treatment Options in Relapsed/Refractory Multiple Myeloma
June 28th 2019

Treatment Options in Relapsed/Refractory Multiple Myeloma

Reimbursement of Subcutaneous Versus IV Dosing in Multiple Myeloma
June 28th 2019

Reimbursement of Subcutaneous Versus IV Dosing in Multiple Myeloma

OCM Ensures Better Outcomes and Automatic Cost Savings in Multiple Myeloma
June 28th 2019

OCM Ensures Better Outcomes and Automatic Cost Savings in Multiple Myeloma

The Impact of OCM in the Treatment of Multiple Myeloma
June 28th 2019

The Impact of OCM in the Treatment of Multiple Myeloma

Entering a 4-Drug Regimen for Multiple Myeloma Treatment
June 28th 2019

Entering a 4-Drug Regimen for Multiple Myeloma Treatment

MAIA Trial: Transplant-Ineligible Patients With MM
June 28th 2019

MAIA Trial: Transplant-Ineligible Patients With MM

Using MRD Negativity to Stop Maintenance Therapy in MM
June 28th 2019

Using MRD Negativity to Stop Maintenance Therapy in MM

Long-term Data on Improving OS for Patients With MM
June 28th 2019

Long-term Data on Improving OS for Patients With MM

Payer Perspective: Transplant and Toxicities in MM Therapy
June 28th 2019

Payer Perspective: Transplant and Toxicities in MM Therapy

FORTE Trial: Transplant in Patients with Multiple Myeloma
June 28th 2019

FORTE Trial: Transplant in Patients with Multiple Myeloma

Impact of Maintenance Therapy in Multiple Myeloma
June 28th 2019

Impact of Maintenance Therapy in Multiple Myeloma

Strategy for Up-front Therapy of Multiple Myeloma
June 28th 2019

Strategy for Up-front Therapy of Multiple Myeloma

Backbone Therapy in Newly Diagnosed Multiple Myeloma
June 28th 2019

Backbone Therapy in Newly Diagnosed Multiple Myeloma

How Real-World Data Can Address Problems in MM
June 28th 2019

How Real-World Data Can Address Problems in MM

<1
...
91011121314151617
...
26>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo